

# U.S. Update on SIV Surveillance and Research

**Amy L. Vincent, DVM, PhD**

Veterinary Medical Officer  
Virus and Prion Diseases Research Unit  
National Animal Disease Center  
USDA-ARS, Ames, IA

# Acknowledgments


## NADC

- Michelle Harland
  - Gwen Nordholm
  - Phil Gauger
  - Pravina Kitikoon
  - Jamie Henningson
  - Matt Sandbulte
  - Daniela Rajao
  
  - Kelly Lager
  - Crystal Loving
  - Mark Kehrli
  - Doug Braucher
  - Janice Zanella
  - Eraldo Zanella
  - Alessio Lorusso
  - Jason Huegel
  - Jason Crabtree
  - Susan Brockmeier
  - David Alt
  - Darrell Bayles
- Sabrina Swenson
  - John Korslund
  - Marie Gramer
  - Bruce Janke
  - Nicola Lewis
  - Daniel Perez
  - Richard Webby
  - James Roth
  - Ruben Donis
  - Sasha Klimov
  - Hana Golding
  - Surender Khurana
  
  - U.S. Producers and Swine Vets


- Funding:  
**USDA-ARS**  
**USDA-APHIS**  
**National Pork Board**  
**CDC**




What information will we gain from the USDA SIV surveillance data?





# UM-VDL Subtype




# ISU-VDL: HA Subtype




# USDA SIV Surveillance by Subtype 10/1/2009-1/31/2012



# Hemagglutinin Gene – Segment 4





# Antigenic Cartography – swine H1



- Cross-HI assays
  - ●  $\alpha$  = classic-like
  - ●  $\beta$  = rH1-like swH1
  - ●  $\gamma$  = IN/00 or H1N2-like
  - ●  $\delta$  = human-like
  - ● 2009 pH1N1
- Important for virus evolution, vaccine strain selection, HI antigen selection, etc.
- H1 serum panel shared among OFFLU SIV group members
- Plan to do H3 viruses this year
- Nicola Lewis



# Reassortants with H1N1pdm09 M gene USDA SIV Surveillance 2010-11



# H3N2 + H1N1pdm09 Reassortants


## H3N2 SIV 8 gene constellations 2009-2011

- North American H3 and N2 human lineage
- TRIG<sup>a</sup> avian lineage
- pandemic H1N1 origin
- TRIG swine lineage

Strain name	Host	PB2	PB1	PA	HA	NP	NA	M	NS
A/IN/08/2011 <sup>b</sup>	human								
A/Sw/IL/A010201606/2011 <sup>b,c</sup>	swine								
A/Sw/NY/A01104005/2011	swine								
A/Sw/IA/A01049750/2011 <sup>Ⓢ</sup>	swine								
A/Sw/TX/A01049914/2011 <sup>Ⓢ</sup>	swine								
A/Sw/TX/A01049915/2011 <sup>Ⓢ</sup>	swine								
A/Sw/TX/A01049555/2011 <sup>Ⓢ</sup>	swine								
A/Sw/TX/A01049556/2011 <sup>Ⓢ</sup>	swine								
A/Sw/KS/11-101926/2011 <sup>Ⓢ</sup>	swine								
A/Sw/KS/11-104465/2011 <sup>Ⓢ</sup>	swine								
A/Sw/KS/11-104467/2011	swine								
A/Sw/KS/11-107824/2011 <sup>Ⓢ</sup>	swine								
A/Sw/KS/11-109700/2011 <sup>Ⓢ</sup>	swine								
A/Sw/KS/11-110529/2011 <sup>Ⓢ</sup>	swine								
A/Sw/KS/10-91088/2010 <sup>Ⓢ</sup>	swine								
A/Sw/IA/A01049034/2010 <sup>Ⓢ</sup>	swine								
A/Sw/IA/A01049035/2010 <sup>Ⓢ</sup>	swine								
A/Sw/MN/239105/2009 <sup>Ⓢ</sup>	swine								
A/Sw/PA/62170-1/2010 <sup>b</sup>	swine								
A/Sw/IN/A01076191/2010 <sup>Ⓢ</sup>	swine	*	*	*					
A/Sw/MN/A01076196/2010 <sup>Ⓢ</sup>	swine								
A/Sw/NC/A01076199/2010 <sup>Ⓢ</sup>	swine	*							
A/Sw/NC/A01076204/2010 <sup>Ⓢ</sup>	swine								
A/Sw/NC/A01076212/2010 <sup>Ⓢ</sup>	swine								
A/Sw/MN/A01076218/2010 <sup>Ⓢ</sup>	swine	*							
A/Sw/NC/A01076178/2009 <sup>Ⓢ</sup>	swine			*					



# Select novel viruses for *in vivo* study



A/IN



Sw/PA



Sw/IL

**H3N2 with TRIG was most virulent and efficient in transmission kinetics. H3N2v was least, but all 3 were pathogenic in swine. Unclear if there is a selective advantage for pM in swine.**

# VAERD

## Vaccine-Associated Enhanced Respiratory Disease

- $\delta$ 1-H1N2 vaccine with H1N1pdm09 H1N1 challenge
- Whole Virus Inactivated + Oil-in-Water Emulsion Adjuvant (KV)
- Naïve pigs, ~4 weeks of age
- 2 doses, 3 weeks apart
  - Intramuscular route
- Challenge 3 or 6 weeks post boost
  - Intratracheal route
  - Intranasal route
  - $10^3$  or  $10^5$  TCID<sub>50</sub> challenge dose
- Monovalent or bivalent vaccines
  - Vaccines induces cross-reacting whole-virus antibodies that **do not cross-react by HI or SN**



# VAERD Vaccine Summary

	Monovalent KV	KV mismatch H1/H3	KV match- mismatch H1/H1	AdV (IN/IM)	MLV
Cross-HI Ab	?	?	?	?	?
Cross-reacting IgG	?	?	?	?	?
Cross-reactive mucosal IgA	?	?	?	IN	?
Cross-reacting CMI	?	?	?	?	?
Macroscopic pneumonia	?	?	?	?	?
Microscopic pneumonia	?	?	?	?	?
Tracheitis	?	?	?	?	?
Nasal shedding	?	?	?	?	?
Clinical Disease	?	?	?	?	?

- Mechanism may be initiated by cross-reacting but non-neutralizing IgG antibody, but role of CMI not to be excluded.
  - Quality versus Quantity of immune response?
    - Ratio of HA2 to HA1 antibodies may be important
- Has real implications for the swine population with multiple subtype variants and vaccine practices.
  - Implications in humans?

Non-Protective/Enhanced	?
Neutral	?
Protective	?
Unknown	?

# VAERD Model

## Possible Mechanisms

- Dysregulated pro-inflammatory & antiviral response
- Neutrophil influx
- Complement activation
- Opsonized uptake of virus
- Cell Mediated Immunity (CTL)

Cause or Effect?

